235 related articles for article (PubMed ID: 31515129)
1. Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model.
Jog NR; McClain MT; Heinlen LD; Gross T; Towner R; Guthridge JM; Axtell RC; Pardo G; Harley JB; James JA
J Autoimmun; 2020 Jan; 106():102332. PubMed ID: 31515129
[TBL] [Abstract][Full Text] [Related]
2. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis.
Cortese M; Leng Y; Bjornevik K; Mitchell M; Healy BC; Mina MJ; Mancuso JD; Niebuhr DW; Munger KL; Elledge SJ; Ascherio A
JAMA Neurol; 2024 May; 81(5):515-524. PubMed ID: 38497939
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus nuclear antigen-1 B-cell epitopes in multiple sclerosis twins.
Mechelli R; Anderson J; Vittori D; Coarelli G; Annibali V; Cannoni S; Aloisi F; Salvetti M; James JA; Ristori G
Mult Scler; 2011 Nov; 17(11):1290-4. PubMed ID: 21757535
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
Ruprecht K; Wunderlich B; Gieß R; Meyer P; Loebel M; Lenz K; Hofmann J; Rosche B; Wengert O; Paul F; Reimer U; Scheibenbogen C
J Neuroimmunol; 2014 Jul; 272(1-2):56-61. PubMed ID: 24798244
[TBL] [Abstract][Full Text] [Related]
6. Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis.
Tschochner M; Leary S; Cooper D; Strautins K; Chopra A; Clark H; Choo L; Dunn D; James I; Carroll WM; Kermode AG; Nolan D
PLoS One; 2016; 11(2):e0147567. PubMed ID: 26849221
[TBL] [Abstract][Full Text] [Related]
7. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis.
Jafari N; van Nierop GP; Verjans GM; Osterhaus AD; Middeldorp JM; Hintzen RQ
J Clin Virol; 2010 Sep; 49(1):26-31. PubMed ID: 20638898
[TBL] [Abstract][Full Text] [Related]
8. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.
Lünemann JD; Jelcić I; Roberts S; Lutterotti A; Tackenberg B; Martin R; Münz C
J Exp Med; 2008 Aug; 205(8):1763-73. PubMed ID: 18663124
[TBL] [Abstract][Full Text] [Related]
9. Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis.
Thomas OG; Haigh TA; Croom-Carter D; Leese A; Van Wijck Y; Douglas MR; Rickinson A; Brooks JM; Taylor GS
PLoS Pathog; 2024 Jun; 20(6):e1012177. PubMed ID: 38843296
[TBL] [Abstract][Full Text] [Related]
10. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
11. Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: A peptide microarray-based case-control study.
Schlemm L; Giess RM; Rasche L; Pfuhl C; Wakonig K; Behrens JR; Scheibenbogen C; Bellmann-Strobl J; Paul F; Reimer U; Ruprecht K
J Neuroimmunol; 2016 Aug; 297():56-62. PubMed ID: 27397076
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr Functional Mimicry: Pathogenicity of Oncogenic Latent Membrane Protein-1 in Systemic Lupus Erythematosus and Autoimmunity.
Munroe ME; Anderson JR; Gross TF; Stunz LL; Bishop GA; James JA
Front Immunol; 2020; 11():606936. PubMed ID: 33613527
[TBL] [Abstract][Full Text] [Related]
13. An Epstein Barr virus-related cross reactive autoimmune response in multiple sclerosis in Norway.
Vaughan JH; Riise T; Rhodes GH; Nguyen MD; Barrett-Connor E; Nyland H
J Neuroimmunol; 1996 Sep; 69(1-2):95-102. PubMed ID: 8823380
[TBL] [Abstract][Full Text] [Related]
14. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.
Jilek S; Schluep M; Meylan P; Vingerhoets F; Guignard L; Monney A; Kleeberg J; Le Goff G; Pantaleo G; Du Pasquier RA
Brain; 2008 Jul; 131(Pt 7):1712-21. PubMed ID: 18550621
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.
Ascherio A; Munger KL; Lennette ET; Spiegelman D; Hernán MA; Olek MJ; Hankinson SE; Hunter DJ
JAMA; 2001 Dec; 286(24):3083-8. PubMed ID: 11754673
[TBL] [Abstract][Full Text] [Related]
16. Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L.
Lindsey JW; deGannes SL; Pate KA; Zhao X
Mol Immunol; 2016 Jan; 69():7-12. PubMed ID: 26637929
[TBL] [Abstract][Full Text] [Related]
17. Antibodies from Multiple Sclerosis Brain Identified Epstein-Barr Virus Nuclear Antigen 1 & 2 Epitopes which Are Recognized by Oligoclonal Bands.
Wang Z; Kennedy PG; Dupree C; Wang M; Lee C; Pointon T; Langford TD; Graner MW; Yu X
J Neuroimmune Pharmacol; 2021 Sep; 16(3):567-580. PubMed ID: 32808238
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P
Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431
[TBL] [Abstract][Full Text] [Related]
19. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.
Sundström P; Juto P; Wadell G; Hallmans G; Svenningsson A; Nyström L; Dillner J; Forsgren L
Neurology; 2004 Jun; 62(12):2277-82. PubMed ID: 15210894
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients.
Deeba E; Koptides D; Gaglia E; Constantinou A; Lambrianides A; Pantzaris M; Krashias G; Christodoulou C
Mol Immunol; 2019 Jan; 105():270-275. PubMed ID: 30562647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]